Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of Vitamin D in GVHD prophylaxis in allogeneic stem cell transplantation (Pilot phase II)
2024-518738-97-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cholecalciferol in hematopoietic malignancies and graft-versus-host disease (GVHD) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoint: Reducing the severity of GVHD. Planned start Nov 2024; status: authorised.
02
Drugs
cholecalciferol
03
Conditions
hematopoietic malignanciesgraft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2024-518738-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518738-97-00.